Key facts
- Renasant Bio’s last known valuation is $78.0M (Jun 2025).
- It has raised $55.5M across 2 recorded rounds; the latest was Early Stage VC ($30.0M) in Jun 2025.
- Notable investors include Qiming Venture Partners USA, OrbiMed, Atlas Venture, 5AM Ventures, Yale School of Medicine.
- Renasant Bio has filed 2 Form Ds with the SEC, most recently Jul 2025 ($25.5M sold to 3 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Renasant Bio
Funding rounds
2 roundsAbout Renasant Bio
Operator of a biopharmaceutical research platform intended to develop oral small-molecule therapies for genetic kidney disorders. The company's platform advances corrector and potentiator programs that target the underlying biology of autosomal dominant polycystic kidney disease, enabling nephrologists, healthcare providers, and patients with disease-modifying treatment options.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2022
- Employees
- 27
- Website
- renasantbio.com/
- Ownership
- Privately Held (backing)
Renasant Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Renasant Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Renasant Bio in its N-PORT filings yet. We sweep new filings monthly.